Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458208 | 0.89 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2PLAUNPC1 | |
| SCHEMBL1458001 | 0.89 | NR1H4 (0.55) | TAS1R3TAS1R1TAS1R2PLAUNPC1 | |
| SCHEMBL9944224 | 0.88 | MAPT (0.52) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL9944170 | 0.84 | KMT2A (0.64) | TAS1R3TAS1R1TAS1R2PLAUNPC1 | |
| SCHEMBL9944185 | 0.81 | PLAU (0.58) | TAS1R3TAS1R1TAS1R2PLAUNPC1 | |
| SCHEMBL9944187 | 0.81 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL9944161 | 0.81 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL1458529 | 0.79 | MEN1 (0.56) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL9944178 | 0.79 | PLAU (0.58) | TAS1R3TAS1R1TAS1R2PLAUNPC1 | |
| SCHEMBL9944231 | 0.78 | MAPT (0.53) | NPC1RAB9AKMT2AMEN1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | TAS1R3 1123/4885TAS1R1 693/4885TAS1R2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.